Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
Objectives:
1.1 To determine the efficacy, as measured by 6 month progression-free survival, of therapy
with thalidomide combined with CPT-11 in the treatment of patients with recurrent and/or
progressive malignant gliomas.
1.2 To determine the rate of measureable clinical response in patients treated with
Thalidomide and CPT-11.
1.3 To determine Thrombotic thrombocytopenic purpura (TTP), overall survival and unexpected
toxicity of Thalidomide and CPT-11 used in recurrent malignant gliomas.
1.4 To determine changes in dynamic magnetic resonance imaging (MRI) as a surrogate marker
for treatment effect.